Antibiotics R&D takes another hit as Achaogen slashes research ops in reorganization
There’s more bad news for the antibiotics R&D field Thursday evening.
A few weeks after the FDA green-lighted Achaogen’s $AKAO antibiotic Zemdri (plazomicin) for urinary tract infections but shunted aside their application on bloodstream infections, the biotech is laying off rank-and-file researchers and letting go its top research execs.
Altogether the company says it is cutting 80 jobs — 28% of the staff — as it chops spending on early-stage research and development, technical operations and general and administrative expenses.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.